White Paper: Why Annex 1 Is Important to You
May 12, 2017
This white paper details the key reasons for the revision to EudraLex Volume 4, Annex 1: Manufacture of Sterile Medicinal Products. It outlines what you should be asking yourself regardless of the dosage form you are responsible for. It also includes a simple tool to assess the impact on your organization when there is a regulatory change.
How NSF Can Help You
Get in touch to find out how we can help you and your business thrive.
What’s New with NSF
NSF Annual Review and Impact Report 2025 Now Live
April 20, 2026NSF has published its Annual Review and Impact Report 2025, detailing the organization’s progress over the past year and outlining strategic priorities for 2026.
Visit NSF at Making Pharma 2026
April 10, 2026Connect with our experts to discover how we help leading pharmaceutical and biotechnology companies achieve regulatory compliance and operational excellence.